Managing systemic sclerosis-related interstitial lung disease in the modern treatment era

Journal of Scleroderma and Related Disorders

Volumn 2, Issue 2, 2017, Pages 72-83

  Volkmann, Elizabeth R ^a   Chung, Augustine ^a   Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interstitial lung disease; Systemic sclerosis; Treatment

Indexed keywords

ABATACEPT; ABITUZUMAB; AZATHIOPRINE; BELIMUMAB; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DABIGATRAN; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; NINTEDANIB; PIRFENIDONE; POMALIDOMIDE; RIOCIGUAT; RITUXIMAB; TADALAFIL; TOCILIZUMAB;

COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG TRANSPLANTATION; MULTIPLE SCLEROSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC SCLEROSIS;

EID: 85052220883     PISSN: 23971983     EISSN: 23971991     Source Type: Journal    
DOI: 10.5301/jsrd.5000237     Document Type: Review

References (93)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51(6):1017-1026.
2. Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33(9):1789-1801.
3. De Santis M, Bosello S, La Torre G, et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005;6(1):96.
4. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-1815.
5. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-3970.
6. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25): 2655-2666.
7. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993;20(5):838-844.
8. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132(12):947-954.
9. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2016 Nov 9:1-13. doi:10.1136/annrheumdis-2016-209909. [Epub ahead of print].
10. Goldin J, Elashoff R, Kim HJ, et al. Treatment of sclerodermainterstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009;136(5):1333-1340.
11. Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011;21(12):2455-2465.
12. Haubitz M. Acute and long-term toxicity of cyclophosphamide. Transplantationsmedizin. 2007;19:26-31. Available from http://www.transplantation.de/fileadmin/transplantation/txmedizin/txmedizin_2007_2/04_haubitz.pdf. Accessed March 27, 2017.
13. Tashkin DP, Roth MD, Clements PJ, et al; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719.
14. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-1034.
15. Sullivan K. Progressive deterioration of patients with scleroderma with pulmonary involvement: 11-year outcomes from the scleroderma lung study (SLS 1) [Oral Presentation]. 3rd Systemic Sclerosis World Congress. Rome; February 6-8, 2014. Abstract S.11.2. Available from http://www.clinexprheumatol.org/article.asp?a=8193. Accessed March 27, 2017.
16. Mittoo S, Wigley FM, Wise RA, Woods A, Xiao H, Hummers LK. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J. 2011;5(1):1-6.
17. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48(12):1595-1599.
18. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosisa retrospective analysis. Rheumatology (Oxford). 2007;46(3):442-445.
19. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455-460.
20. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-OCallaghan A, Solans-Laqué R, Vilardell-Tarrés M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011;30(11):1393-1398.
21. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30-36.
22. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150-155.
23. Saketkoo L, Lammi M, Fischer A, Molitor J, Steen V. Observations from the pulmonary hypertension recognition and outcomes in scleroderma (Pharos) Cohort [Abstract]. Ann Rheum Dis. 2015;74(Suppl 2):820.
24. Zheng Y, Li M, Zhang Y, Shi X, Li L, Jin M. The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int. 2010;30(3):341-348.
25. Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate versus placebo for patients with systemic sclerosis-related interstitial lung disease [Abstract 824]. Arthritis Rheumatol. 2016;68(Suppl 10). Available from http://acrabstracts.org/?advanced=1&mworthyauthor=Volkmann&s=. Accessed March 27, 2017.
26. Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheum (Munch). 2015;67(5):1314-1322.
27. Khan IY, Singer LG, de Perrot M, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013;107(12):2081-2087.
28. Sottile PD, Iturbe D, Katsumoto TR, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation. 2013;95(7):975-980.
29. Crespo MM, Bermudez CA, Dew MA, et al. Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes. Ann Am Thorac Soc. 2016; 13(6):784-792.
30. Miele CH, Schwab K, Saggar R, et al. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Ann Am Thorac Soc. 2016;13(6):793-802.
31. Patti MG, Vela MF, Odell DD, Richter JE, Fisichella PM, Vaezi MF. The Intersection of GERD, Aspiration, and Lung Transplantation. J Laparoendosc Adv Surg Tech A. 2016;26(7):501-505.
32. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of longterm treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2)(Suppl 71):S17-S22.
33. Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4): 428-436.
34. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). 2008;47(4):552-553.
35. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271-280.
36. Ebata S, Yoshizaki A, Fukasawa T, et al. Unprecedented success of rituximab therapy for prednisolone-and immunosuppressantresistant systemic sclerosis-associated interstitial lung disease. Scand J Rheumatol. 2016 Nov 30:1-3. doi: 10.1080/03009742.2016.1231341. [Epub ahead of print].
37. Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015;14(11):1072-1078.
38. Jordan S, Distler JH, Maurer B, et al. EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-1194.
39. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-2640.
40. Tashkin DP, Volkmann ER, Tseng CH, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis. 2016;75(2):374-381.
41. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71(7):1235-1242.
42. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001;27(2): 140-146.
43. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004;138(3): 540-546.
44. Abdel-Magied RA, Kamel SR, Said AF, Ali HM, Abdel Gawad EA, Moussa MM. Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(4): 321-330.
45. Dumoitier N, Chaigne B, Regent A, et al. Scleroderma peripheral B lymphocytes secrete interleukin-6 and TGF-beta and activate fibroblasts. Arthritis Rheum (Munch). In press.
46. Feghali CA, Bost KL, Boulware DW, Levy LS. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity. 1994;17(4):309-318.
47. van Laar JM, Farge D, Sont JK, et al. EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498.
48. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110(4):1388-1396.
49. Sullivan K, Keyes-Elstein L, McSweeney P, et al. Myeloablative autologous transplantation of CD34+ -selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CYC) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial [Abstract 6L]. Arthritis Rheumatol. 2016;68 (Suppl 10). Available from http://acrabstracts.org/abstract/myeloablative-autologous-transplantation-of-cd34-selectedhematopoietic-stem-cells-hsct-vs-monthly-intravenous-cyclophosphamide-cyc-for-severe-scleroderma-with-internal-organ-involvement-outcom/. Accessed March 27, 2017.
50. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycinmediated lung fibrosis. J Clin Invest. 2004;114(9):1308-1316.
51. Prey S, Ezzedine K, Doussau A, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167(5):1138-1144.
52. Distler O, Distler J, Varga J, et al. A multicenter, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [Abstract]. Arthritis Rheum. 2010;62 Suppl 10:560. DOI: 10.1002/art.28329.
53. Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75(5):883-890.
54. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22): 2083-2092.
55. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1-3):400-408.
56. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1): L311-L318.
57. Khanna D, Albera C, Fischer A, et al. Safety and toleratbility of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease: The LOTUSS study [Abstract 3134]. Ann Rheum Dis. 2015;74(816). Available from http://acrabstracts.org/abstract/safety-and-tolerability-of-pirfenidone-in-patients-with-systemicsclerosis-interstitial-lung-disease/. Accessed March 27, 2017.
58. Hsu V, Denton C, Domsic R, et al. A Phase 2 Study of pomalidomide (CC-4047) to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and effectiveness in subjects with systemic sclerosis with interstitial lung disease [Abstract 823]. Arthritis Rheumatol. 2016;68(Suppl 10). Available from http://acrabstracts.org/abstract/a-phase-2-study-of-pomalidomidecc-4047-to-evaluate-safety-tolerability-pharmacokinetics-pharmacodynamics-and-effectiveness-in-subjects-with-systemicsclerosis-with-interstitial-lung-disease/. Accessed March 27, 2017.
59. Gordon J, Pelrine E, Lee Y, et al. Safety and efficacy of belimumab with background mycophenolate for early diffuse cutaneous systemic sclerosis: a randomized, placebo controlled, pilot trial [Abstract 3247]. Arthritis Rheumatol. 2016;68(Suppl 10). Available from http://acrabstracts.org/abstract/safetyand-efficacy-of-belimumab-with-background-mycophenolatefor-early-diffuse-cutaneous-systemic-sclerosis-a-randomizedplacebo-controlled-pilot-trial/. Accessed March 27, 2017.
60. Parida J, Nath A, Neyaz Z and Agarwal V. A double blind randomized control trial of oral tadalafil in interstitial lung disease in scleroderma [Abstract 1679]. Arthritis Rheumatol. 2014; 66(Suppl 10). Available from http://acrabstracts.org/abstract/adouble-blind-randomized-control-trial-of-oral-tadalafil-in-interstitial-lung-disease-of-scleroderma/. Accessed March 27, 2017.
61. Chakravarty EF, Martyanov V, Fiorentino D, et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2015;17(1):159.
62. Koca SS, Ozgen M, Dagli F, et al. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation. 2012;35(3):810-817.
63. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum. 2009;60(11): 3455-3464.
64. Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol. 2011;2011:829751.
65. Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. Semin Arthritis Rheum. 2016;S0049-0172(16)30464-4.
66. Kwon HM, Kang EH, Park JK, et al. A decision model for the watchand-wait strategy in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2015;54(10):1792-1796.
67. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248-1254.
68. Wells AU. Interstitial lung disease in systemic sclerosis. Presse Med. 2014;43(10 Pt 2):e329-e343.
69. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283-1289.
70. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum (Munch). 2014;66(6):1625-1635.
71. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62(2):146-150.
72. Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63(10):3078-3085.
73. Moore OA, Goh N, Corte T, et al. Extent of disease on highresolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013;52(1):155-160.
74. Hoffmann-Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheum (Munch). 2015;67(8):2205-2212.
75. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8): 2246-2255.
76. Domsic RT, Nihtyanova SI, Wisniewski SR, et al. Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheum (Munch). 2016;68(4):993-1003.
77. Mendoza F, Derk CT. Systemic sclerosis mortality in the United States: 19992002 implications for patient care. J Clin Rheumatol. 2007;13(4):187-192.
78. Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken). 2013;65(8):1375-1380.
79. Khanna D, Nagaraja V, Tseng CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015;17(1):372.
80. Roth MD, Tseng CH, Clements PJ, et al. Scleroderma Lung Study Research Group. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011;63(9):2797-2808.
81. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994;37(9): 1290-1296.
82. Volkmann ER, Tashkin DP, Roth MD, et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther. 2016;18(1):305.
83. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
84. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758.
85. Kangalee KM, Abboud RT. Interlaboratory and intralaboratory variability in pulmonary function testing. A 13-year study using a normal biologic control. Chest. 1992;101(1):88-92.
86. Tashkin DP, Volkmann ER, Tseng CH, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis. 2016;75(2):374-381.
87. Mayo JR, Hartman TE, Lee KS, Primack SL, Vedal S, Müller NL. CT of the chest: minimal tube current required for good image quality with the least radiation dose. AJR Am J Roentgenol. 1995;164(3):603-607.
88. Goldin J, Beckett K. Risks of thoracic CT. In: Barr RG, Parr DG, Vogel-Claussen J, eds. Imaging. Plymouth, UK: European Respiratory Society 2015;253-262.
89. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008;15(8):1004-1016.
90. Kim HG, Tashkin DP, Clements PJ, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. 2010;28(5)(Suppl 62):S26-S35.
91. Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev. 2013;22(129):236-243.
92. Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35(6):1064-1072.
93. Iudici M, Cuomo G, Vettori S, et al. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum. 2015;44(4):437-444.